First-Line Medication for Agitation and Combativeness in an 84-Year-Old Female
Quetiapine is the first-line pharmacologic choice for this patient, as it demonstrated the lowest adverse event rate (OR 0.27) compared to haloperidol in the most recent 2025 geriatric emergency guidelines systematic review. 1
Critical Safety Evidence
The 2025 JAGS systematic review analyzing 838 older adults provides the strongest recent evidence for medication selection based on adverse event profiles 1:
- Quetiapine had significantly fewer adverse events (OR 0.27 [95% CI: 0.08,0.97]) compared to haloperidol
- Avoid benzodiazepines entirely - midazolam had a 53% adverse event rate with OR 5.25 for harm compared to haloperidol
- Overall adverse events occurred in 16.8% of older adults receiving these medications
Treatment Algorithm
Step 1: Attempt Non-Pharmacologic Interventions First
Before any medication, try person-centered communication, sensory therapy, and environmental modifications 1. However, when these fail or dangerous agitation exists, proceed immediately to pharmacologic treatment.
Step 2: Choose Quetiapine as First-Line
- Start with low doses given the geriatric population
- Monitor for respiratory depression, hypotension, QTc prolongation, and delirium exacerbation 1
- Document baseline and ongoing SAS (Sedation-Agitation Scale) scores 2
Step 3: Alternative Options if Quetiapine Unavailable or Ineffective
Second-line choices based on evidence:
- Olanzapine - recommended by multiple sources for lower adverse effects 3, 4, though not specifically studied in the 2025 geriatric safety review
- Haloperidol - acceptable baseline comparator but higher adverse event rate than quetiapine 1
- Citalopram 20mg daily - consider when safety is paramount and agitation is chronic rather than acute 5, 6, though note cognitive worsening and QTc concerns at higher doses
Critical Pitfalls to Avoid
Never use benzodiazepines (lorazepam, midazolam) as first-line in this age group - they carry excessive risk with OR 5.25 for adverse events 1. This contradicts older practice patterns but is supported by the strongest recent evidence.
Do not combine medications initially - while older literature suggested combination therapy 7, the 2025 geriatric safety data emphasizes monotherapy to minimize adverse events 1.
Avoid prolonged use - the APA guideline emphasizes that antipsychotic benefits in dementia are "at best small" with consistent mortality risks 8. Reassess frequently and discontinue when possible.
Context-Specific Considerations
If this is dementia-related agitation (most likely in an 84-year-old):
- Quetiapine remains first-line based on safety profile 1
- Brexpiprazole has strongest efficacy evidence but may not be available 5
- Consider citalopram 20mg if chronic management needed 5, 6
If this is acute severe agitation requiring rapid control:
- Quetiapine still preferred for safety 1
- Intramuscular olanzapine is alternative if oral not feasible 3, 4
- Document restraint use as it correlates with appropriateness of treatment 2
Monitoring Requirements
- Cardiovascular: QTc interval, blood pressure, arrhythmias 1
- Respiratory: Oxygen saturation, respiratory rate 1
- Neurologic: Delirium assessment, extrapyramidal symptoms, falls 1
- Effectiveness: SAS scores, restraint needs, as-needed dose frequency 2
The evidence strongly contradicts traditional benzodiazepine use in geriatric agitation - this represents a significant shift from older practice patterns that must be recognized and avoided.